Back to Mirati Therapeutics


Manufactured By:
Mirati Therapeutics
3545 Cray Court
San Diego CA 92121
United States


Sitravatinib is a spectrum-selective kinase (RTK) inhibitor that can potentially stimulate the body's immune response to fight cancer.

At this time enrollment to a Mirati clinical trials with sitravatinib is the only way to receive  sitravatinib.  Further information is available on the Mirati website.

Please note, that Mirati does not currently provide access to sitravatinib outside of enrollment in a clinical trial.  

For information on Mirati clinical trials, please visit or visit Mirati Clinical Trials.